Gilead Sciences, Menarini Group and Haisco Pharmaceutical Group side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Gilead Sciences | Menarini Group | Haisco Pharmaceutical Group |
|---|---|---|---|
| Phase 1 | Gilead Sciences: 6 of its 32 programs at phase 1 and 1 more — sign in to see them all | Menarini Group: 4 of its 7 programs at phase 1
| Haisco Pharmaceutical Group: 14 of its 27 programs at phase 1 and 9 more — sign in to see them all |
| Phase 2 | Gilead Sciences: 6 of its 32 programs at phase 2
and 1 more — sign in to see them all | Menarini Group: 2 of its 7 programs at phase 2
| Haisco Pharmaceutical Group: 5 of its 27 programs at phase 2 |
| Phase 3 | Gilead Sciences: 15 of its 32 programs at phase 3
and 10 more — sign in to see them all | Menarini Group: 1 of its 7 programs at phase 3
| Haisco Pharmaceutical Group: 7 of its 27 programs at phase 3
and 2 more — sign in to see them all |
| Approved, new studies | Gilead Sciences: 5 of its 32 programs at approved, new studies
| 00% | Haisco Pharmaceutical Group: 1 of its 27 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences10 readouts · 2 phase 3 | · | Gilead Sciences, Dec ’26: 2 programs whose next study reaches primary completion
| · | · | Gilead Sciences, Mar ’27: 4 programs whose next study reaches primary completion
| · | · | Gilead Sciences, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| · | Gilead Sciences, Aug ’27: 2 programs whose next study reaches primary completion
| · | · |
| Menarini Group3 readouts · 0 phase 3 | Menarini Group, Nov ’26: 1 program whose next study reaches primary completion
| · | · | · | · | · | · | · | · | · | · | Menarini Group, Oct ’27: 2 programs whose next study reaches primary completion
|
| Haisco Pharmaceutical Group9 readouts · 1 phase 3 | Haisco Pharmaceutical Group, Nov ’26: 2 programs whose next study reaches primary completion
| Haisco Pharmaceutical Group, Dec ’26: 3 programs whose next study reaches primary completion
| · | · | Haisco Pharmaceutical Group, Mar ’27: 1 program whose next study reaches primary completion
| · | · | Haisco Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | · | Haisco Pharmaceutical Group, Sep ’27: 1 program whose next study reaches primary completion
| · |
Changed in the last 90 days
Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Gilead Sciences
New programs 2
- GS-1179phase 2 · first study · Oct 28
- PTM Cilofexor Dose Aphase 2 · first study · Sep 21 · Liver Cirrhosis, Biliary
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 6
- Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 1 · Jun 2029 → Dec 2031 (+30 mo) · moved Nov 17 · NCT07304154
- seladelparphase 2 · Jun 2028 → Dec 2028 (+6 mo) · moved Oct 27 · NCT07841977
- anitocabtagene autoleucelphase 1 · Mar 2027 → Oct 2028 (+19 mo) · moved Oct 22 · NCT06626919
- bictegravirphase 3 · Nov 2026 → Jul 2030 (+44 mo) · moved Sep 29 · NCT06532656
- lenacapavirphase 3 · Nov 2026 → Jul 2030 (+44 mo) · moved Sep 29 · NCT06532656
- Autologous Anti-CD19/CD20 CAR-T Cells KITE-363phase 1 · Jul 2029 → Sep 2030 (+14 mo) · moved Sep 28 · NCT07038447
Menarini Group
New programs 0
None
Reached a new phase 1
- KAT6 Inhibitor MEN2312phase 2 · Oct 8 · Breast Neoplasms
Study stopped 0
None
Primary completion later 1
- RPX7009phase 2 · Jul 2026 → Oct 2027 (+15 mo) · moved Oct 7 · NCT06828848
Haisco Pharmaceutical Group
New programs 1
- HSK60002 tabletsphase 1 · first study · Oct 16 · Dermatitis, Atopic
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.